Breast Cancer Clinical Trial
Official title:
European Cooperative Study of Chemotherapy and Surgery Comparing Adjuvant Doxorubicin Followed by CMF vs. Adjuvant Doxorubicin/Paclitaxel Followed by CMF vs. Primary Doxorubicin/Paclitaxel Followed by CMF in Women With Operable Breast Cancer and T>2 cm
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells.
It is not yet known which treatment regimen is more effective for breast cancer.
PURPOSE: Randomized phase III trial to study the effectiveness of chemotherapy plus surgery
in treating women who have breast cancer.
OBJECTIVES:
- Evaluate whether 8 courses of primary chemotherapy before adequate surgery of breast
tumor and locoregional radiotherapy plus tamoxifen for 5 years improves the
disease-free and overall survival in women with operable breast carcinoma and tumor at
diagnosis greater than 2 cm in diameter.
- Assess whether, in the postoperative arms, the addition of paclitaxel to doxorubicin
before CMF (cyclophosphamide, methotrexate, and fluorouracil) improves disease-free and
overall survival in these patients.
- Define the incidence of pathologic complete response (CR) induced by 8 courses of
primary chemotherapy containing paclitaxel.
- Assess whether a pathologic CR is an independent predictor of disease-free and overall
survival.
- Evaluate the effects of primary chemotherapy on the rate and quality of breast
conserving surgery.
OUTLINE: This is a randomized, multicenter study. Patients are stratified by center, tumor
diameter at mammography, nuclear or histological grade, and estrogen/progesterone receptor
status. Patients are randomized to one of three treatment arms.
- Arm I: Patients receive doxorubicin IV over 15 minutes once every 3 weeks for 4
courses. Beginning 21 days after the last administration of doxorubicin, patients
receive cyclophosphamide IV, methotrexate IV, and fluorouracil IV on days 1 and 8.
Treatment repeats every 28 days for 4 courses in the absence of disease progression or
unacceptable toxicity.
- Arms II and III: Patients receive doxorubicin IV over 15 minutes and paclitaxel IV over
3 hours once every 3 weeks for 4 courses. Beginning 21 days after the last
administration of doxorubicin and paclitaxel, patients receive cyclophosphamide IV,
methotrexate IV, and fluorouracil IV on days 1 and 8. Treatment repeats every 28 days
in the absence of disease progression or unacceptable toxicity.
All patients have either mastectomy or breast conserving surgery; patients with unclear
surgical margins may have second surgery (re-resection or total mastectomy) or radiotherapy.
Lymph node axillary dissection is performed up to at least the second level. For patients in
the 2 adjuvant arms (arms I and II), adjuvant chemotherapy starts by day 21 after surgery.
For patients in the primary chemotherapy arm (arm III), surgery is performed by day 28 after
the last course of chemotherapy or at resolution of all possible hematological or infective
complications.
At the end of the combined surgery plus chemotherapy approach (i.e., after the last course
of CMF (arms I and II) or after surgery (arm III)), patients enrolled after June 30, 2000
with estrogen or progesterone receptor positive disease receive oral tamoxifen daily for 5
years.
All patients who have breast conserving surgery receive postoperative irradiation within 4
weeks after completing chemotherapy and surgery (i.e., within 4 weeks from last dose of
adjuvant chemotherapy (arms I and II) or from surgery (arm III)). All patients who have
mastectomy and have pT4 disease must receive irradiation to the chest wall.
Patients are followed at 6, 12, 18, and 24 months, and then annually thereafter.
PROJECTED ACCRUAL: A total of 450 patients per arm will be accrued for this study within 5
years.
;
Allocation: Randomized, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |